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Abstract
An important goal of cancer genomic research is to identify the driving pathways underlying
disease mechanisms and the heterogeneity of cancers. It is well known that somatic ge-
nome alterations (SGAs) affecting the genes that encode the proteins within a common sig-
naling pathway exhibit mutual exclusivity, in which these SGAs usually do not co-occur in a
tumor. With some success, this characteristic has been utilized as an objective function to
guide the search for driver mutations within a pathway. However, mutual exclusivity alone is
not sufficient to indicate that genes affected by such SGAs are in common pathways. Here,
we propose a novel, signal-oriented framework for identifying driver SGAs. First, we identify
the perturbed cellular signals by mining the gene expression data. Next, we search for a set
of SGA events that carries strong information with respect to such perturbed signals while
exhibiting mutual exclusivity. Finally, we design and implement an efficient exact algorithm
to solve an NP-hard problem encountered in our approach. We apply this framework to the
ovarian and glioblastoma tumor data available at the TCGA database, and perform system-
atic evaluations. Our results indicate that the signal-oriented approach enhances the ability
to find informative sets of driver SGAs that likely constitute signaling pathways.
Author Summary
An important goal of studying cancer genomics is to identify critical pathways that, when
perturbed by somatic genomic alterations (SGAs) such as somatic mutations, copy num-
ber alterations and epigenomic alterations, cause cancers and underlie different clinical
phenotypes. In this study, we present a framework for discovering perturbed signaling
pathways in cancers by integrating genome alteration data and transcriptomic data from
the Cancer Genome Atlas (TCGA) project. Since gene expression in a cell is regulated by
cellular signaling systems, we used transcriptomic changes to reveal perturbed cellular
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signals in each tumor. We then combined the genomic alteration data to search for SGA
events across multiple tumors that affected a common signal, thus identifying the candi-
date members of cancer pathways. Our results demonstrate the advantage of the signal-
oriented pathway approach over previous methods.
Introduction
Somatic genome alterations (SGAs) such as somatic mutations, somatic copy number alter-
ations and epigenomic alterations are major causes of cancers[1–3]. In general, SGAs in a
tumor can be divided into two types: those that affect cellular signaling proteins, perturb the
cellular signaling system, and eventually contribute to cancer initiation and progression are
called driver SGAs; and those that do not directly contribute to cancer development are desig-
nated as passenger SGAs. A fundamental problem of cancer-genome research is to identify sig-
naling pathways that, when perturbed by driver SGAs, lead to cancer development or affect
clinical outcomes for patients. Identification of such pathways will not only advance our under-
standing of the disease mechanisms underlying cancer, but will also provide guidance for the
precision treatment of cancer patients.
In a cell, signaling pathways detect and transmit cellular signals to maintain cellular homeo-
stasis; often, such signals eventually regulate the transcription of genes in order to initiate cer-
tain biological processes. For example, the signal transmitted by a growth factor usually leads
to the transcription of genes involved in cell proliferation (Fig 1). As such, the impact of an
SGA affecting a signaling protein in a tumor often manifests as an expression signature embed-
ded in the expression profile of the tumor. For example, a mutation leading to constitutive acti-
vation of the epidermal growth factor receptor (EGFR) gene may lead to over-expression of its
target genes. Thus, the gene expression profile of a cell at a given time reflects the state of its cel-
lular signaling system, although it is a convoluted response to all active signals. Inferring the
state of an individual pathway requires the deconvolution of the signals embedded in its gene
expression data. The Cancer Genome Atlas (TCGA) has collected the most comprehensive ge-
nome-scale data to date, including somatic mutations, copy number variations, and gene ex-
pression from a large number of different types of cancers. By simultaneously capturing SGAs
and gene expression data from each tumor, the TCGA data reflect the cause and readout of per-
turbed signaling pathways, thus providing a unique opportunity for studying cancer pathways.
Identification of perturbed and critical signaling pathways using the TCGA data is challeng-
ing in the following ways. First, as a cancer cell usually hosts dozens to hundreds of SGAs, we
need to identify the small number of driver SGAs among the large number of passenger SGAs
within a given tumor. Current approaches for identifying driver SGAs mainly concentrate on
those that occur beyond random chance in a patient population[4–7]. These approaches would
fail to find low-prevalence SGAs that affect a specific cancer-driving pathway. The second chal-
lenge is caused by the heterogeneity of mutations in tumor cells, in that few tumors have identi-
cal SGA patterns. One reason for this phenomenon is that a signal pathway can be perturbed
in multiple locations[8], and different tumors may share a common aberrant pathway but ex-
hibit SGAs affecting distinct proteins on the pathway. Thus, it is a challenge to determine if dis-
tinct SGA events in different tumors affect a common pathway. Finally, a cancer results from
perturbations in multiple pathways[2], and distinct combinations of pathway perturbation un-
derlie the heterogeneity of cancers[2] in terms of clinical phenotype. Thus, it is a challenge to
determine, among multiple SGAs and multiple aberrant pathways in a tumor, which SGA af-
fects which pathway.
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Researchers have developed various approaches to search for driving pathways using TCGA
by exploiting different properties of tumor cells[9–11], including mutual exclusivity[12–14],
which is the observed phenomenon that SGA events affecting the proteins within a signaling
pathway seldom co-occur in a tumor. A natural explanation for this phenomenon is that, if one
mutation is sufficient to perturb the signal of a pathway and leads to the development of can-
cer, perturbation of other proteins is not required, and therefore co-occurrence of perturba-
tions is seldom observed. This property is observed in different types of cancer cells and
pathways[4,13,15,16].
While it is the case that SGAs affecting the genes within a common pathway tend to be mu-
tually exclusive, the reverse may not necessarily be the case, that is, finding a set of mutually ex-
clusive SGAs does not ensures that their corresponding proteins are in the same pathway.
Current mutual-exclusivity-based methods[12–14,16,17] concentrate on finding a set of SGAs
of size k, such that the set covers as many tumors as possible while minimizing overlapping
cover (thus maximizing mutual exclusivity). As the numbers of tumors and SGAs examined by
contemporary genome technology increase, it becomes increasingly easier to find a set of unre-
lated SGAs that covers a certain number of tumors while exhibiting mutually exclusivity due to
the heterogeneity of tumors. To address this shortcoming, Zhao et al[14] further considered
the co-expression of SGA-affected genes in order to enhance the search of pathways. The intui-
tion underlying their approach is that proteins within a signaling pathway tend to be co-ex-
pressed, so the correlation of the expressions of the candidate genes of a pathway can be used
Fig 1. A diagram reflecting the signaling systems of a cancer cell. A signal pathway usually consists of a
cascade of proteins, represented as rectangle (receptors) and circle (intracellular) nodes. Different pathways
transmit signals regulating expression of distinct sets of target genes. In cancers, a pathway can be perturbed
by an SGA event affecting a member protein (indicated by a red node); a cancer cell usually has multiple
pathways perturbed.
doi:10.1371/journal.pcbi.1004257.g001
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as another objective function to guide pathway search. Both mutual exclusivity and co-expres-
sion of SGAs are auxiliary properties of a signaling pathway, but they are not sufficient to indi-
cate whether the SGAs affect a common cellular signal; therefore, they are useful but not the
optimal objective function to guide the search for a signaling pathway.
In this study, we propose a novel signal-oriented framework for searching cancer pathways
by combining gene expression with SGA data. The premise underlying our approach is as fol-
lows: since the state of a signaling pathway can be reflected by the expression state of a set of
genes it regulates (i.e., its signature), the task of searching for a pathway can be formulated as a
search for a set of SGAs that collectively exhibit strong information with the state of a gene ex-
pression signature. Under such a setting, mutual exclusivity and co-expression of SGA-affected
genes can further be used as auxiliary objective functions to constrain the search space and to
enhance the confidence of the results. This approach addresses the fundamental task of the
pathway discovery—finding a set of SGAs perturbing a common signal.
We applied this novel framework to the ovarian cancer and glioblastoma data from TCGA,
followed by systematically evaluating the impact of the signal-oriented approach on the search
for driving pathways and comparing the performance of our exact algorithm with that of heu-
ristic or stochastic algorithms. We show that the signal-oriented approach provides a general
framework in which different pathway-searching algorithms can be combined with different
signal-oriented objective functions (beyond those discussed here) to explore new directions for
studying cellular signaling systems.
Materials and Methods
The overall framework of this study is shown in Fig 2, which consists of the following steps to
search for a set of mutually exclusive driver SGAs that affect a common signal: 1) We first iden-
tified differentially expressed genes from each tumor, and then grouped genes into non-disjoint
functional sets according to their Gene Ontology[18] (GO) annotation using the methods pre-
vious developed by our group [19–21], such that functions of the genes in a set are coherently
related to each other and are summarized by a GO term from the Biological Process Domain of
the GO (Fig 2A). 2) After selecting the differentially expressed genes annotated with a common
GO term across tumors, we constructed a bipartite graph consisting of tumors on one side and
the genes on the other side, and we then searched for a densely connected subgraph (Fig 2B).
We hypothesized that, if a set of genes that are coherently related (sharing a common GO an-
notation) and co-differentially expressed in multiple tumors, they are likely regulated by a
common signal that is perturbed in these tumors. Thus, the genes constitute a gene expression
module responding to the signal. We refer to such a module as a “response module” (RM). 3)
We then designed an exact algorithm to search for a set of SGAs that are
significantly enriched in the tumors in which an RM was perturbed, with the constraint that
the SGAs in the solution set exhibited a mutually exclusive pattern among tumors in the RM
(Fig 2C).
Data pre-processing
Data on somatic mutation, copy number alteration, and gene expression from 568 ovarian can-
cer tumors and 513 glioblastoma tumors, as well as 8 normal control samples from ovarian tis-
sue and 10 cases of normal brain samples were downloaded from the TCGA[4,5]. For each
tumor, we considered a gene as being differentially expressed if its expression value increased
or decreased at least 3-fold in comparison to the median value of the gene in the control sam-
ples. We defined a gene as affected by an SGA event if it had a non-synonymous single nucleo-
tide variation in its coding region, and/or an insertion or a deletion; we also labeled a gene as
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affected by an SGA event if it had copy number alteration (with the GISTIC[22] score 2 and
z-score 1.64 or GISTIC score -2 and z-score -1.64, where the z-score is obtained by the
z-transformation of the expressions of the gene across all tumors). Hence, only the copy num-
ber alterations that affected gene expression (with a p-value of 0.05) are included. We removed
the genes that exhibit both amplifications and deletions (with the smaller fraction being over
10%) in a given set of tumors that are supposed to have a common signal perturbed as incon-
sistent genes. For example, if a gene X is affected by copy alteration, where 85% of events are
amplification and 15% are deletion (thus smaller fraction is over 10%), we would remove this
gene from the consideration. This is a relatively conservative consideration of those genes with
consistent copy number alteration direction as potential drivers. Finally, if two genes exhibit
perfect correlation (co-amplified or co-deleted whenever altered), we treat these genes as one
common genomic alteration. These procedures lead to a tumor-by-gene binary matrix record-
ing differentially expressed genes, and a tumor-by-gene binary matrix recording SGA events
in tumors.
Identifying gene modules as signal-response units
To deconvolute signals embedded in the gene expression data, we hypothesized that if a set of
genes performs coherently related functions and tends to be co-regulated in multiple tumors,
the genes are likely regulated by a common signaling pathway as a module. To find such mod-
ules among the cancer tumors, we employed a knowledge-driven data mining approach, devel-
oped in our previous studies[19–21], which consists of two major procedures: 1) identifying
functionally coherent gene subsets among the differentially expressed genes in each tumor,
such that each gene subset is annotated by a GO term that summarizes the function of the
genes; and 2) further identifying the gene subsets that are differentially expressed in multiple
Fig 2. Overall scheme. A) Use GO structure and semantic information to categorize differentially expressed genes in each tumor into functionally coherent
subgroups. B) Find a dense bipartite sub-graph (DBSG) consisting of a subset of genes and a subset of tumors, such that the genes in the DBSG form a
response module (an RM) to a perturbed signal in the tumors.C) Search for SGAs perturbing a signal regulating an RM. First, assess the strength of the
associations (the enrichment weight) between SGA-affected genes and an RM. Then find a set of SGAs that are mutually exclusive and that cover a
maximum number of tumors in the DBSG; minimize the weight sum of the SGAs in the solution, and you have theweighted mutually exclusive maximum set
cover problem. Note that SGA-affected genes are denoted with the lower case, while differentially expressed genes are rendered in the upper case.
doi:10.1371/journal.pcbi.1004257.g002
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tumors, which is formulated as the dense bipartite subgraph finding problem. Researchers
have used set cover[23,24] or the extension of the set cover –module cover [25] model to find
gene subsets that are differentially expressed because of pathway perturbation. Our two-step
method differs from these in that genes included in each solution subset are both functionally
coherent and co-expressed in a considerable number of tumors. We also obtained the tumors
that perturb the pathways regulating the expression of each gene subset.
To identify functionally coherent gene subsets, we first found a tumor’s differentially ex-
pressed genes and grouped them into non-disjoint subsets by mining their annotations [19–
21]. This was achieved by representing the hierarchical structure of GO terms as a directed acy-
clic graph and searching for genes annotated with closely related GO terms. We first associated
genes to the GO terms according to annotations of the genes. We then iteratively merged high-
ly specific GO terms and their associated genes to their parent GO terms according to a proce-
dure [19] that strives to minimize the loss of semantic information during the process. In this
fashion, we can group genes annotated with closely related terms into a set annotated with a
more general GO term that retains the information of the original annotations. We stop the
procedure if a further merge leads to a non-coherent gene set, according to a quantitative met-
ric that assesses the statistical significance of functional coherence of the gene set [19,21]. This
procedure enabled us to partition differentially expressed genes from each tumor into non-dis-
joint, functionally coherent subsets.
Next, we further identified the functionally coherent gene subsets that are affected in multi-
ple tumors. We modeled this problem as a dense bipartite subgraph (DBSG) finding problem,
of which the detailed algorithm was introduced in our previous work[21]. Briefly, we pooled
gene subsets annotated with a common GO concept across all tumors and constructed a bipar-
tite graph, in which the vertices on one side represent the pool of differentially expressed genes
sharing the GO annotation, and the vertices on the other side represent the tumors; an edge be-
tween a gene and a tumor indicates that the gene is differentially expressed in the tumor. We
then searched for a subset of genes that are co-differentially expressed in multiple tumors. We
formulated our task as follows: find a maximum dense bipartite subgraph such that each gene
must be connected to at least 75% (a connectivity ratio) of all tumors in the subgraph and each
tumor must be connected to at least 75% of all genes in the subgraph. Thus, each DBSG con-
sists of a set of genes, i.e., an RM, and a set of tumors in which the RM is perturbed.
An exact algorithm for finding a minimum-weight, mutually exclusive set
To search for the candidate members of a signaling pathway regulating an RM, we aimed to
find a set of SGA-affected genes that has the following properties: 1) the SGA events affecting
the genes cover as many as possible of the tumors in which the RM of interest is perturbed; 2)
the SGA events carry strong information with respect to the expression state of an RM, or, in
other words, the SGAs are significantly enriched in tumors in which RMs have been perturbed;
and 3) each tumor is covered by only one gene in the solution set (thus mutually exclusive.
Note: SGA events are only mutually exclusive among tumors in each DBSG). By assigning a
weight to each SGA to reflect the amount of information the SGA carries with respect to the state
of the RM, we formulate this computational problem as the weighted mutually exclusive maxi-
mum set cover problem, a variant of the well-known set cover problem in algorithm theory[26].
To assess the strength of association of an SGA-affected gene (a genome locus) with the
state of an RM, we apply a hypergeometric test to compute the enrichment of the SGA events
of the gene in tumors within which the RM has been perturbed[27]. We then set the log p-
value of the SGA enrichment analysis as the weight for the gene; thus, a set of SGAs with a
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smaller total weight tends to carry more information with respect to the RM when compared
to another gene set with a greater total weight.
Fig 2C illustrates the problem setting as follows. Of the 16 tumors and 5 genes in a dataset
(Fig 2C), 6 tumors are included in a DBSG. We define that a tumor is covered by a gene if an
SGA affecting the gene occurs in the tumor; we then represent each gene by the subset of tu-
mors in the DBSG it covers. In our example, g1 = {T1, T2}, g2 = {T3, T4, T5}, g3 = {T1, T4,
T5}, g4 = {T1, T3}, and g5 = {T2, T5, T6}. For each DBSG, we define the set of all tumors in the
DBSG, X, as the ground set; for example, in the figure, X = {T1, T2, T3, T4, T5, T6}. We define
F as the set of the candidate genes; in our example, F = {g1, g2, g3, g4, g5} = {{T1, T2}, {T3,
T4, T5}, {T1, T4, T5}, {T1, T3}, and {T2, T5, T6}}. We define w: F! (-1,1); the function w
gives weight to each gene. Given a subset of genes, F 0  F , if no two elements in F 0 have any
common element, i.e., if no two genes cover the same tumor, we then say that F 0 is mutually
exclusive; the weight of F 0 is
P
S2F 0 w(s). The problem’s goal is to find a mutually exclusive
subset of F that covers a maximum number of elements of X (i.e., that covers a maximum
number of tumors). If we find two or more solutions, e.g., {g1, g2} and {g4, g5}, that cover the
maximum number of elements, we choose the solution with the minimum weight, {g1, g2}.
This is the formal definition of the weighted mutually exclusive maximum set cover problem.
As is the case with the formulations of other studies on mutual exclusivity[12–14,16,17],
our problem is NP-hard (see the proof in a separate technical report[28]). Previous studies
used heuristic or stochastic algorithms [12–14,16,17] to handle the mutually exclusive set cover
problem or its variants, but such algorithms do not guarantee the finding of optimal solutions.
In this study, we developed an exact algorithm, called the WeightedMutually Exclusive Maxi-
mum Set Cover algorithm (or theME algorithm), that guarantees the finding of exact optimal
solutions. The algorithm uses parameterized techniques[29], such that the running time is an
exponential function of a parameter that can be bounded by a small number for certain specific
applications, instead of the exponential functions of large input sizes that are generally used
for solving general NP-hard problems. Because our problem involves about 600 tumors and
30,000 genes, an exponential function of any of these input sizes would be intractable. However,
using the parameterized technique, we developed an algorithm whose worst time complexity is
O(1.325m), wherem, the parameter, is the number of candidate genes when we search driver
SGAs affecting a pathway. In fact, the actual running time of the algorithm is much smaller than
that of the worst time complexity; the algorithm can finish our computation task on a worksta-
tion in 5 to 10 minutes, even whenm is 200, which is sufficiently large candidate size for search-
ing driver SGAs that perturb a signaling pathway. We refer to a set of solution SGAs as
perturbation module (PM) to reflect that they may perturb a common signaling pathway.
Our method adopts a branch-and-bound principle: the algorithm first finds a subset in F ,
and then branches on it. Due to the mutual exclusivity constraint, if any two subsets in F over-
lap, then at most only one of them can be chosen into the solution. For example, suppose that
the subset S intersects with other d subsets in F ; then, if S is included into the solution, S and
other d subsets intersecting with S will be removed from the problem, and if S is excluded from
the solution, S will be removed from the problem. We continue this process until the resulting
sub-problems can be solved in constant or polynomial time. Let T(m) be the number of com-
putations needed when call the algorithm withm subsets in F , then we can obtain the recur-
rence relation T(m) T(m−(d+1))+T(m−1). As if d = 0 for all subsets in F , the problem can
be solved in polynomial time (all subsets in F will be included into the solution), in the recur-
rence relation, d 1. Therefore, we can obtain T(m) 1.619m, which means the problem can
be solved in O(1.619m) time (note: Given the recurrence relation T(k) ∑0  i  k-1 ciT(i)
such that all ci are nonnegative real numbers, ∑0  i  k-1 ci> 0, and T(0) represents the leaves,
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then T(k) rk, where r is the unique positive root of the characteristic equation tk- ∑0  i  k-1
cit
i = 0 deduced from the recurrence relation[30]). We improved the algorithm’s running time
by carefully selecting subsets in F for branching. As the proof of the algorithm is very involved,
we present the details in the technical report[28].
We have implemented all algorithms for the paper. Supplement results and codes for algo-
rithms can be found at: http://pitttransmed-tcga.dbmi.pitt.edu/mutuallyExclusive/.
Results
Identify RMs to reveal perturbed cellular signals
Using the integrated knowledge-mining and data-mining approaches, we identified 88 dense
bipartite subgraphs (DBSGs) from the ovarian cancer tumors. Each DBSG includes a response
module (RM) consisting of at least 10 genes that are differentially expressed in 30 or more tu-
mors. Based on our functional coherence analysis, the genes in an RM were functionally related
to each other. To further corroborate these results, we also evaluated the RMs using the Inge-
nuity Pathway Analysis (IPA— http://www.ingenuity.com/); each of our RMs was found to sig-
nificantly overlap with at least one of the IPA networks. For example, we found 55 RMs, of
which more than 90% of their genes overlapped with at least one network from the Ingenuity
network database (results are presented in a supplementary website so that researchers can
browse the RMs and their driver SGAs).
As an example, an RM that consists of 11 genes (AURKA, CCNB1, CHEK1, COL5A1,
EPHB3, NEK2, PSRC1, STMN1, TACC3, THBS2, TWIST1) that are up-regulated in 62 tumors.
The biological processes in which the genes are involved are summarized by the GO term
GO:0051128: Regulation of Cellular Component Organization (note: because genes in each RM
are annotated by a GO term, we use GO term IDs to name RMs and PMs; we also use U_ or
D_ to indicate whether genes in the RM are up-regulated or down-regulated, respectively). For
example, the designation “RM U_GO0051128”means that the genes in the RM are up-regulat-
ed and that they are annotated by the GO term GO:0051128; “PM D_GO0009611” is the PM
that regulates the RM D_GO0009611). We found that 10 of those 11 genes are in an IPA net-
work (Fig 3) that is labeled as “Cellular Assembly and Organization, Cellular Function and
Maintenance, Cell Morphology”. Previous laboratory studies show that 9 of these genes play im-
portant roles in tumor initiation and progression in different types of cancers. For example,
AURKA was found overexpressed in the early stage ovarian tumors, therefore suggesting that
the alteration of AURKA could be an early event of ovarian cancer[31]. High levels of AURKA
expression is closely correlated to poor survival of patients with ovarian cancer [32]. The prolif-
eration-related targets AURKA and CCNB1 were overexpressed in clinical ovarian tumor speci-
mens[33]. Our predicted results corroborate with the established roles of AURKA and CCNB1
in cancers. In addition, many references also show that overexpression of seven of the remain-
ing nine genes in the RM are related to cancers (S1 Table).
Another example of a cancer-related RM, annotated with the GO term GO:0010564 (Regu-
lation of Cell Cycle Process), includes 10 genes (BIRC5, CCNB2, CDC7, CDKN2A, CENPE,
CENPF, CHEK1, NEK2, TIMELESS, UBE2C) that are up-regulated in 140 tumors. All of those
10 genes are in an IPA network related to “Cell Cycle, DNA Replication, Recombination, and
Repair, Cellular Assembly and Organization” (see Supplement). A literature search shows that
9 of 10 genes in the module are related to several types of cancers (S2 Table). Among them, ex-
pression of CENPE and CCNB2 correlates with worse clinical outcomes of patients with breast
or ovarian cancers [34–36]. The fact that the genes in these RMs are functionally coherently re-
lated and co-regulated in multiple tumors from different types of tumors indicates that their
aberrant expression is likely regulated by a common signal; thus, expression state of an RM can
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be utilized as the readout of the state of a hidden signal, allowing the search for the SGA events
perturbing the signal. One interesting observation in this RM is that the CDKN2A, a tumor
suppressor, is overexpressed. By checking the copy number alteration data, we found that the
overexpression of CDKN2A in most of 140 tumors were not caused by the gene amplification.
The similar phenomenon was observed in large number of tumors in other tumor types, such
as GBM and HNSC, where the CDKN2A was overexpressed in almost all tumors without
CDKN2A amplifications. The explanation of this phenomenon needs the further study from
cancer biologists.
This framework was also applied to TCGA data of glioblastoma multiform (GBM), the
most malignant cancer in the brain, and we identified 101 RMs. Comparing RMs in GBM with
ones in ovarian cancer, 38 RM pairs were annotated by an identical GO term in both ovarian
cancer and GBM, among which 17 modules are significantly overlapped (p-value and q-value
of overlapping< 10–4, S3 Table). For example, the RMs annotated with U_GO0007067 (mitot-
ic nuclear division) found from GBM and ovarian cancer have 18 and 17 genes respectively, in
which 15 genes are in common, and the union of the two RMs includes 20 genes. As expected,
literature studies indicate that almost all the above genes and most of other significant overlap-
ping RMs are related to cancers (S4 Table), including those involved in U_GO0009611 (re-
sponse to wounding) and U_GO0006974 (cellular response to DNA damage stimulus). Thus the
approach of searching RMs as reflections of perturbed cellular signals is generalizable to differ-
ent types of cancers and capable of finding cancer-related RMs.
We further investigated if the expression states of RMs are relevant to patients’ clinical out-
comes, we dichotomized GBM patients from TCGA according to the expression state of each
RM, followed by survival analysis. We found the expression states of 25 RMs are associated
with significant differences in patients’ survival (p-values< 0.05 and q-values< 0.05 for
Kaplan-Meier analysis, see S5 Table and S1 Fig). We also applied these methods to the breast
cancers from TCGA for searching RMs (data not shown). We used the breast cancer RMs as
Fig 3. Overlapping of genes in RM U_GO0051128 with an IPA network. A total of 10 out of 11 genes in
the RM overlap with an IPA network (highlighted).
doi:10.1371/journal.pcbi.1004257.g003
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features for predicting survival of the patients studied by Curtis et al [37] in an open research
challenge (the DREAM 7 Challenge), in which RMs were found to be highly predictive of pa-
tient survival [38]. Therefore, the expression states of RMs reflect the states of cancer cells,
which is determined by cellular signal transduction pathways.
Finding SGAs underlying RMs
We hypothesized that the differential expression of an RM in a tumor is due to the aberrant sig-
nal resulting from pathway perturbation by at least one of the SGAs (somatic genome alter-
ations) observed in the tumor. Since somatic copy number alterations are common in ovarian
cancers (which may contribute to differential expression of genes), we first examined if identi-
fied RMs are driven by copy number alterations. For each RM, we treat differential expression
of a gene in a tumor as a differential expression event. We also define that it is driven by a copy
number alteration event if the gene is copy number altered in the tumor. We then calculated
the fraction of copy-number-alteration-driven differential expression events for each module
and averaged them across the RMs, which shows that, on average, only 3.4% of differential ex-
pression events are likely driven by copy number alteration. The results support our hypothesis
that the differential expression of an RM is driven by a pathway rather than by direct copy
number alterations. As such, a reasonable strategy for identifying the signaling pathway regu-
lating the RM is to pool the tumors in which the RM is differentially expressed and further
search for a subset of the SGA events in these tumors that carries the strongest information
with respect to the expression state of the RM. We refer to a module of genes affected by such
SGAs as a “perturbation module” (PM).
When given a DBSG, we first identified all SGA events observed in the tumors within it, and
then calculated enrichment of SGAs affecting a gene using a hypergeometric test, assigning the
enrichment p-value as the weight of the gene. We applied the ME algorithm to identify an opti-
mal PM for each DBSG, using up to 200 SGAs with the lowest p-values as input, a sufficiently
large number when considering that most known biological pathways contain around tens of
proteins. The sizes of the returned PMs ranged from 3 to 14 genes, with an average of 7.14.
Since our algorithm strives to include SGAs that are specifically enriched in the tumors in a
DBSG, the genes in a PM as a whole are highly enriched in the tumors in a DBSG, with enrich-
ment p-values ranging from 5.68×10−4 to 7.16×10−25 (median: 8.97×10−14).
Since SGA events are in effect randomized perturbatons performed by nature, a strong cor-
relation between SGA events and the expression state of an RM suggests that SGAs influence
gene expression rather than the reverse direction (differential gene expression causing SGAs).
Thus, genes in each PM identified in our study are likely members of the signaling pathway
perturbed in tumors that underlie the differential expression of the genes in an RM. Though ex-
perimental validation of the results could be conclusive, it is extremely costly. Therefore, we
validated our results by comparing them to the existing knowledge using the IPA package, with
the understanding that while the knowledge base of the IPA may be incomplete, it is, nonethe-
less, an accessible approach. Our findings indicated that most PMs were significantly associated
with different diseases and/or disorders (65 PMs with both p-values and q-values of at most
0.001, with a median of 9.21×10−4); among them, 30 PMs were related to cancers with both p-
values and q-values smaller than 0.001. We further investigated whether the identified PMs
could be mapped to known signaling pathways, concluding that, indeed, many PMs were en-
riched in known pathways, including 51 PMs that were enriched in a known pathway with
both p-values and q-values of at most 0.01.
As an example, we examined the PM corresponding to the RM studied in the previous sec-
tion, U_GO0051128, which consists of 6 genes (CCNE1, RB1, FRMD1, COLIM4,MAST3,
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RNF139). The genes in the PM are enriched in the IPA pathway “Estrogen-mediated S-phase
Entry” (Fig 4A), with a p-value of 1.83×10–5. This PM has two genes (RB1 and CCNE1) in the
well-characterized RB1 cancer pathway that plays important roles in ovarian cancer tumori-
genesis (Fig 4B) [5]. Golgi integral membrane protein 4 (GOLIM4) is a type II Golgi-resident
protein that involves in processing proteins synthesized in ER and assist in the transport of
protein cargo through the Golgi apparatus[39]. These transported proteins include ones shown
in Fig 4A. Ring finger protein 139 (RNF139) is a multi-membrane spanning protein with ubi-
quitin ligase activity. RNF139 interacts with tumor suppressor VHL and JAB1[40], the latter is
responsible for the degradation of tumor suppressor CDKB1B/p27CIP1 in this pathway (Fig
4A). GOLIM4 and RNF139 in this PM were found as potential cancer drivers in various types
of cancers [41–43]. Additionally,MAST3, RB1, and CCNE1 in this PM are critical in regulating
cell cycle [44–46]. As shown in Fig 4C, the mutually exclusive pattern of the SGAs affects genes
in this PM identified from the 62 tumors in which this RM was perturbed. It is of highly signifi-
cance that our algorithm predicts that the amplification of CCNE1 gene conveys the identical
information as to the mutation or deletion of RB1. As shown in Fig 4B, the protein encoded by
CCNE1 inhibits that of RB1 (Fig 4B); both amplification of CCNE1 and mutation/deletion of
RB1 have the same effect on a common signal, leading to aberrant regulation of cell cycle entry
and thereby causing cancers. Indeed, 6 out of 11 genes in the RM U_GO0051128 are related to
cell cycle. When searching the PASTAA (http://trap.molgen.mpg.de/PASTAA.htm) database
for enriched transcription factor binding sites of genes in this RM, the binding site of E2F1 (a
transcription factor directly downstream of RB1) was the most significantly enriched region in
the promoters of the genes in this RM (S6 Table). Thus, our algorithm correctly identified a
perturbed signaling pathway and its downstream target genes. Fig 4D further shows that pro-
teins encoded by the genes in the PM U_GO0051128 directly interact with other well-known
oncogenes, such as TP53,MDM4, CCND1, CCND2,MYC, E2F3, E2F5, BRCA2, PTEN,MET,
and COPS5 (S7 Table). Thus, the results indicate that the signal-oriented approach leads to bio-
logically sensible findings. However, a challenging issue of handling copy number alteration is
that a set of genes can be co-amplified (co-deleted) within highly overlapping but not perfectly
identical copy number alteration fragments in different tumors. Thus, it would be difficult to
differentiate the signals of such alterations. For example, RNF139, TRMT12, ZNF572, SQLE,
MYC and other genes are often co-amplified but not perfectly correlated in various types of
cancers including ovarian cancer(S2 Fig), among whichMYC is a known cancer driver gene in
numerous types of cancers[47]. When examining other genes in this region, we found that cer-
tain amplification events were not associated with corresponding gene expression changes,
hence disqualifying these alterations as a potential driving event. Our algorithm returned
RNF139 in the solution because the perturbation events of RNF139 (copy number alteration of
a gene with associated expression change) had strongest information with respect to this RM.
While the signal of RNF139may be convoluted with those of the other genes in the fragment,
there is evidence that RNF139 contributes to cancer development by regulating tumor suppres-
sors p27 and VHL[40] that are both critical in cancer development[48,49]. Our results indicate
that our methods are capable of identifying the copy number alteration fragment that has
strong information with respect to an RM as well as finding the most representative gene. The
latter is closely related to the capacity of finding the peak of a commonly amplified or deleted
region[50]. However, determination of whether this representative gene is an authentic driver
requires thorough interrogation of neighboring genes followed by experimental validation.
Next, we examined another perturbation module PM D_GO0006915 obtained from TCGA
GBM data. The module has five genesMLLT3, NF1,MDM2, LRP1, and COL24A1.MLLT3,
NF1, and COL24A1 are either deleted or mutated whileMDM2 is amplified in tumors (Fig 4E).
We found that the genomic alterations of these genes suppress the expressions of a set of genes
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Fig 4. The PM corresponding to RM U_GO0051128. A) Overlap between the PMU_GO0051128 and a known pathway.B) Overlap of the PM
U_GO0051128 with the RB pathway.C) SGA pattern of the PMU_GO0051128. D) Genes in the PM U_GO0051128 closely interacting with
other oncogenes. E) SGA pattern of the PMD_GO0006915.
doi:10.1371/journal.pcbi.1004257.g004
Identifying Driver Genomic Alterations in Cancers
PLOS Computational Biology | DOI:10.1371/journal.pcbi.1004257 August 28, 2015 12 / 20
related to apoptotic process of cells. TheMDM2 is a well-known oncogene that inhibits tumor sup-
pressor p53 function [51–53]. Inhibition ofMDM2 induces cell apoptosis [54,55] and reactivates
p53 in GBM cells, resulting in inhibition of GBM cell growth in vitro and in GBM xenografts in
mice[56]. Thus, it is plausible that amplification ofMDM2 in the module PMD_GO0006915 will
inhibit cell apoptosis. Inactivation ofNF1 by germline mutations are predisposed to the develop-
ment of benign and malignant tumors of peripheral and central nervous system including GBMs
[57,58]. Loss of NF1 also renders cancer cell resistant to apoptosis [59]. On the other hand, forced
expression ofMLLT3, which is deleted in the module PMD_GO0006915, significantly increased
cell apoptosis [60]. Lastly, low—density receptor protein 1 (LRP1) activates Akt pro-survival path-
way thereby inhibit cell apoptosis in neurons[61]. Depletion of LRP1 led to an increase in cell apo-
ptosis [61,62], thus corroborating with our findings that amplification of LRP1 inhibits apoptosis.
Since LRP1mutations have not been reported in cancers, we predict that these mutations exert a
similar effect as their gene amplification events. Taken together, our identification of alterations in
this PM in GBM validated the established functions of these oncogenic drivers in tumor initiation
and progression in GBMs and other types of cancers.
Systematic evaluation of the impact of the signal-oriented approach and
use of the exact algorithm on finding PMs
Our framework employed two main innovations. First, we revealed the perturbed cell signals
from each tumor, and we utilized the information to search PMs in a signal-oriented fashion.
Second, we developed an exact algorithm (the ME algorithm) that efficiently solves the weight-
ed mutually exclusive maximum set cover problem. In this section, we systematically evaluate
the impact of the above approaches on revealing cellular signals and identifying the pathways
transmitting them.
1. Evaluation of the impact of the signal-oriented approach on finding PMs. In this
subsection, we assess the impact of signal-oriented approach for identifying tumors with a
common signal perturbed, i.e., identifying tumors in which a common RM is perturbed, on the
quality of PMs from an information-theory point of view. Since it is uncommon that a signal-
ing pathway is universally perturbed in all tumors, a set of SGAs in a PM randomly distributed
among tumors is less likely to affect a specific cellular signal. On the other hand, if the SGAs in
a PM are specifically enriched in a subset of tumors, this PM has high information content
with respect to the input tumors, potentially reflecting a common characteristic shared by the
tumors, such as a common perturbed pathway. Imagine that two methods, A and B, are repeat-
edly used to dichotomize tumors into two subsets, and that a common algorithm is then em-
ployed to search for a PM covering one of them as input. If method A consistently yields an
input set that leads to more informative PMs in comparison to method B, we say that method A
reveals specific information in the tumors. This enables us to determine if our method of finding
a set of tumors sharing a common RM enhances the capability of finding informative PMs.
Based on the above assumptions, we used a well-established program, the De novo Driver
Exclusivity (Dendrix [16]), as an unbiased tool to search for SGAs that cover a set of tumors
with strong mutual exclusivity, in order to assess whether dichotomizing tumors based the ex-
pression states of an RM reveals biological information. Dendrix, developed in a seminal study
by Vandin et al. [16], is a program that searches for driver mutations in a pathway (i.e., a PM)
by exploiting the mutually exclusive property of SGAs. Given a set of tumors and the SGAs ob-
served in the tumors, its task is to find a PM of size k—a parameter to be assigned by a user—
that maximizes the coverage of input tumors while minimizing the overlapping coverage of tu-
mors by SGAs (thus maximizing mutual exclusivity). Due to the NP-hard nature of the prob-
lem, the Dendrix utilizes a Monte Carlo Markov chain approach to address the task. Using a
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set of tumors and their SGAs as input, Dendix returns a collection of SGA sets of size k as can-
didate PMs, and it assigns a weight to each PM to reflect the PM’s quality (the higher, the bet-
ter); this is referred to as the D-weight score in the following discussion.
We applied Dendrix to the tumor set from each of the 88 DBSGs, we also applied Dendrix
to randomly drew 88 tumor sets and with matching sizes (repeated 128 times). In this way, the
DBSG-based input utilized the information that common pathway may be perturbed in the
input tumors (due to the fact that an RM is differentially expressed in them), whereas the ran-
dom tumor sets did not utilized such biological information; we refer to the derived PMs as
DBSG-based and random, respectively, in the following discussion. From each input tumor set,
we specified the parameter k to be the same size as the solution PM returned by our ME meth-
od on the same input, and we selected the solution PM with the best D-weight score in the fol-
lowing analyses. The box plots in Fig 5A illustrate the distribution of the D-weight scores
derived from both the DBSG-based and the random tumor sets. The results indicate that Den-
drix is capable of finding PMs from both DBSG-based and random tumor sets that have similar
coverage and mutual exclusivity. Note that the action of searching for a DBSG and drawing a
random tumor set de facto dichotomized tumors into two groups: input tumors and the rest.
Thus, we were able to calculate the enrichment of the solution SGAs within the input tumor set
(DBSG-based or random) versus that of the rest of the tumors, using a hypergeometric distri-
bution test [27] to assess the quality of returned PMs. Fig 5B shows that the PMs from the
DBSGs are significantly enriched in the input tumors, with a mean of log (base 2) p-values of
Fig 5. The impact of the signal-oriented approach on the qualities of PMs. A) Distributions of D-weight.
B) Distributions of enrichment p-values. (Note: D-weight – the solution weight defined by Dendrix, where a
solution with high coverage (of tumors) and low overlap will have a high score. The Enrichment p-value – the
solution weight defined by our method, where a solution whose somatic mutation and copy number alteration
are enriched in tumors that perturb a common signal will have a good p-value.)
doi:10.1371/journal.pcbi.1004257.g005
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−11.11; on the other hand, the enrichment p-values derived from the random tumor sets are
much less significant, with a mean of log p-values of −1.92 (which corresponds to a p-value of
0.26, a non-significant p-value).
The results described above indicate that the expression states of an RM reflect real biologi-
cal signals shared by a set of tumors, thus enabling Dendrix to identify the candidate driver
SGAs that are strongly associated with specific input tumors. On the other hand, feeding Den-
drix with tumors with no specific information leads to the discovery of uninformative SGAs.
The striking difference is solely due to different inputs, because Dendrix was able to find mutu-
ally exclusive SGA sets that provided equal coverage of tumors from random tumor sets. This
fact, in turn, suggests another important conclusion: that the mutual exclusivity property of a
set of SGAs alone is not sufficient to indicate that the SGAs carry specific information; there-
fore, it should not be the sole objective function to guide the search for signaling pathways.
We further assessed if the Dendrix program could also benefit from the information of RMs
in a quantitative fashion, where such information was provided to the program in the form of
constrained inputs. We ranked SGAs in an ascending order based on the p-value of their en-
richment in tumors aberrantly expressing an RM. As such, the smaller the p-value, the stronger
an SGA is associated with the expression state of an RM. Therefore, from an information view-
point, the more information the SGA carries with respect to the RM. It should be noted that
the most frequent SGA event, TP53 mutations, carries very low amount information with re-
spect to most RMs. We then use the top 200 SGAs as input for the Dendrix program, which is
equivalent to allowing the program to take advantage of the information with respect to an RM
to search a pathway in a signal-oriented fashion. We refer to PMs derived from this experiment
as the Dendrix-top200. When compared to the results from DBSG-based tumor sets without
constraints, the PMs from the Dendrix-top200 experiment were significantly more enriched in
the input tumors, with an average log p-value of −38.24, indicating that the signal-oriented ap-
proach indeed enhances the ability to identify informative SGAs; thus, they are more likely to
be biologically sensible candidates for cancer pathways. Our study in using Dendrix to search
for more informative candidates reflects the generalizability of our signal-oriented approach.
2. The performance of our exact algorithm. In this study, we designed an exact algorithm
to find an optimal PM by pursuing three objectives: 1) that the PM covers the maximal number
of input tumors; 2) that the PM covers the maximal number of input tumors with a minimum
total weight; and 3) that each tumor is covered by at most one gene in the solution. Unlike
greedy or stochastic algorithms (e.g., the Dendrix), an exact algorithm guarantees the finding
of an optimal solution, and thus should out-perform heuristic algorithms. To illustrate this ad-
vantage, we compared the performance of our ME algorithm with that of the Dendrix’s pro-
gram, when both were applied to the 88 DBSGs derived from the TCGA ovarian cancer data.
In order to compare the programs under similar circumstances, we constrained the input
SGA-affected genes to conform to those used in the Dendrix-top200 experiment; we then set
the weight for all input genes to 1 and applied the Dendrix and the ME programs to the data.
We denoted the results from this experiment as “ME-uw,” and we analyzed the enrichment of
PMs in input tumor sets as well as the PMs’D-weight scores in order to compare the
returned results.
As shown in Fig 6, the distributions of the enrichment p-values of the PMs obtained from
the above experiments. As illustrated, the performance of ME-uw is better than that of the
Dendrix-top200. Note that the results are in log space, and that therefore a difference of 4.3 in
the means corresponds to a 19-fold difference in p-values. When we further compared the en-
richment p-values in a pair-wise manner, we found that the ME-uw outperformed the Den-
drix-top200 59 times, whereas the Dendrix-top200 outperformed the ME-uw 23 times. We
then compared the performance of ME-uw and Dendrix-top200 using D-weight scores (the
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objective function explicitly pursued by Dendrix but not by ME). We found that the ME-uw re-
turned a better solution in 33 PMs, whereas the Dendrix-top200 won out in 42 PMs. These re-
sults show that, under identical conditions, stochastic algorithms cannot return optimal
solutions in a considerable number of cases (here, in at least 33 out of 88 cases). Finally, when
the weights of SGAs were considered, the results generated by our ME algorithm further im-
proved upon those of the ME-uw and the Dendrix-top200. We found the mean enrichment p-
value of our regular ME algorithm to be 40-folds better than that of the Dendrix-top200. Com-
pared with the ME-uw, the ME obtained better PMs for 28 DBSGs, while the ME-uw won out
in only 4 cases (with both returning the same PMs in all the remaining cases). By using weight
as a parameter, the algorithm can find PMs that are more informative of the pathways regulat-
ing an RM in a DBSG.
Discussion
The challenge of finding the perturbed signaling pathways that underpin the disease mecha-
nisms and heterogeneity of cancers remains one of the most import areas of cancer genomic re-
search. The future of personalized and precision treatment of cancer patients depends on the
ability to identify those pathways and to infer their perturbation states in individual patients
for the prescribe targeted treatments[3]. While certain auxiliary properties, such as mutual ex-
clusivity and co-expression of candidate members of a pathway, have been applied in searching
signaling pathways with a certain degree of success, these properties are not sufficient for the
goal of pathway search, as demonstrated in this study. In this study, we proposed a framework
that addresses the crux of the pathway-finding problem: identifying proteins that carry a spe-
cific signal. This is achieved by searching for SGAs (a PM) that carry strong information with
respect to the expression state of an RM, which is a surrogate of the state of a signaling path-
way. Since genes in a PM are randomly perturbed by nature, a strong association between
genes in a pair of PM and RM usually indicates that perturbation of genes in a PM causes dif-
ferential expressions of genes in the RM. However, it should be noted that such associations
may also result from a selection bias, for example, mutation of one gene and over-expression of
another are both enriched in a particular tumor subtype, leading to an apparent association
even though they do not have a causal relationship. Therefore, further experiment or detailed
causal analysis is needed to validate the potential causal relationship between the PM and RM.
Our results indicate that the framework is generalizable in that an unbiased program, such as
the Dendrix program, can also benefit from the information of the expression state of RMs to
find more informative SGA sets exhibiting mutual exclusivity. Therefore, one main contribu-
tion of this work is to demonstrate the utility of framework of deconvoluting cellular signals
Fig 6. Comparison of heuristic and exact algorithms. Distributions of enrichment p-values of the PMs
identified by the Dendrix-top200, ME-uw, and ME algorithms.
doi:10.1371/journal.pcbi.1004257.g006
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from molecular phenotypic data, e.g., gene expression data, and then enabling pathway-search-
ing programs to simultaneously combine multiple objective functions relevant to pathway
search, including signal-oriented objective function proposed here, mutual exclusivity of SGAs,
and coexpression of SGA-affected genes.
In this study, we also proposed an exact algorithm to explicitly take into account the amount
of information carried by a set of SGAs with respect to an RM by solving the weighted mutually
exclusive maximum set cover problem. While it is possible to use the mutual information [63]
between the SGA events of a PM and the expression states of a RM—a quantity that is reversely
related to the enrichment p-value—as the goal in searching for a PM, i.e. searching for a maxi-
mum information SGA gene set with respect to a given RM, such formulation will lead to a
computational problem that is much more difficult to solve. The current algorithm requires
that the members in a PM are mutually exclusive, which is a property taken advantage by our
algorithm to yield a practical runtime. In practice, such requirement may be too stringent, lead-
ing to omission of some solutions. In our future research, we plan to relax this requirement
and allow a small degree of overlap into the solution and design an efficient, exact algorithm to
address the new problem.
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